Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patients with renal cell carcinoma.
Kikuchi H, Osawa T, Matsumoto R, Abe T, Maruyama S, Harabayashi T, Miyata H, Kashiwagi A, Ikeshiro S, Sazawa A, Fukui R, Morita K, Takeuchi I, Hori K, Yamashita N, Minami K, Mochizuki T, Murai S, Shinohara N.
Kikuchi H, et al. Among authors: maruyama s.
Urol Oncol. 2022 Jan;40(1):13.e19-13.e27. doi: 10.1016/j.urolonc.2021.09.014. Epub 2021 Oct 27.
Urol Oncol. 2022.
PMID: 34716079
Free article.